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Abstract
Background—Efforts to develop a Clostridium difficile vaccine are underway; identification of 
patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified 
groups at high risk of CDI ≥28 days after hospital discharge.
Methods—Hospital discharge data and pharmacy data from two large academic centers, in New 
York and Connecticut, were linked to active population-based CDI surveillance data from the 
Emerging Infections Program (EIP). Adult residents of the EIP surveillance area were included if 
they had an inpatient stay at a study hospital without prior history of CDI. The primary outcome 
was CDI by either toxin or molecular assay ≥28 days after an index hospitalization. Important 
predictors of CDI ≥28 days post discharge were initially identified through a Cox proportional 
hazards model (stepwise backward selection) using a derivation cohort; final model parameters 
were used to develop a risk score evaluated in the validation cohort.
Results—Of the 35,186 index hospitalizations, 288 (0.82%) had CDI ≥28 days post discharge. 
After parameter selection, age, number of hospitalizations in the prior 90 days, admission 
diagnosis, and the use of 3rd/4th generation cephalosporin, clindamycin or fluoroquinolone 
antibiotic classes remained in the model. Using the validation cohort, the risk score was predictive 
(p<0.001) with a c-score of 0.75. Based on the distribution of scores in the derivation cohort, we 
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divided the patients into low and high risk groups. In the high risk group, 1.6% experienced CDI 
≥28 days post discharge compared to 0.3% among our low risk group.
Conclusions—Our study identified specific parameters for a risk score that can be applied at 
discharge to identify a patient population whose risk of CDI ≥28 days following an acute care 
hospitalization was 5 times greater than other patients.
Keywords
Clostridium difficile infection; administrative data; health care-associated infections; antibacterial 
agents; vaccines
Background
Clostridium difficile was estimated to cause nearly half of a million infections in the United 
States in 2011 and has become the most common pathogen type among healthcare-
associated infections.[1, 2] The U.S. hospital discharge rate with C. difficile infection (CDI) 
listed as any diagnosis increased from 5.6 per 1,000 discharges in 2001 to 11.5 per 1,000 
discharges in 2010, and was projected to continue to increase.[3] In the United States, data 
from vital records showed that C. difficile has become the leading cause of enterocolitis-
associated deaths and was estimated to be associated with nearly 29,000 deaths per year in 
2011.[2, 4] Furthermore, C. difficile is no longer restricted to hospital settings and 
approximately 75% of the patients who develop healthcare-associated CDI have their onset 
outside the hospital settings.[5] Although numerous interventions have been implemented to 
control the spread of C. difficile in hospitals, this pathogen remains an important cause of 
healthcare-associated infections in the United States.[5, 6] Efforts to develop a C. difficile 
vaccine are currently underway and identification of high risk patients to be targeted for 
vaccine trials is critical to measure vaccine efficacy and immunogenicity.
We conducted a retrospective cohort study of hospitalized patients at two large academic 
centers, participating in the Emerging Infections Program (EIP) CDI Surveillance, to 
identify groups at high risk of CDI that could potentially be targeted for vaccine trials.
Methods
Study Settings and Patients
We used data from academic centers in CT with approximately 1,000 beds and 58,000 
discharges per year and NY with approximately 700 beds and 40,000 discharges per year. 
The two academic centers along with their respective state health departments are part of 
EIP.[7] Active population- and laboratory-based surveillance for CDI is ongoing in both 
Monroe County, NY and New Haven County, CT since 2009.[7]
For this study, patients were included if they were ≥18 years of age, had an inpatient stay at 
a study hospital, and were residents of the CT and NY surveillance area.
Data Sources
For this project, we utilized existing data as follows:
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Each participating institution obtained clinical and demographic information from their 
hospital discharge data, including ICD-9-CM procedure and diagnostic codes, patient's age, 
insurance coverage, sex, date of hospital admission and discharge, inpatient unit(s) visited, 
disposition at discharge, and initial diagnosis on admission. Patient identifiers were obtained 
to allow for merging of data with pharmacy and EIP surveillance data.
Pharmacy Data
Data on antibiotic class, name, route, and duration for all antibiotics administered during 
each hospital stay was obtained for hospitalizations in the study period. Antibiotics were 
grouped into the following classes: aminoglycosides, 1st and 2nd generation cephalosporins, 
3rd and 4th generation cephalosporins, lincosamides, fluoroquinolones, macrolides, 
vancomycin, sulfonamides, beta-lactam/beta-lactamase inhibitor combinations, 
carbapenems, penicillins, and miscellaneous. Pharmacy data also contained individual 
patient identifiers to allow merging of pharmacy data with hospital discharge data.
EIP Data
The EIP CDI surveillance provides longitudinal data on CDI among surveillance area 
residents in the community and healthcare settings. Trained epidemiologists capture all C. 
difficile-positive reports by either toxin or molecular assay from clinical, reference, or 
commercials laboratories for residents in the catchment area, along with the personal 
identifiers. A laboratory report is classified as an incident episode if it was in a patient 
without a positive C. difficile test in the prior 8 weeks. All incident episodes receive a 
unique code and are entered on weekly basis into a web-based system without personal 
identifiers. We utilized EIP CDI data from the beginning of surveillance at each site until 
December 2012 to identify patients diagnosed with CDI in outpatient and inpatient settings.
Data Linkage and Transfer to CDC
Each site was responsible for generating a linkable patient identification (LPI) code based on 
patient identifiers that were common across all three datasets. Encounters identified for the 
same patient received the same LPI code, unique to a specific patient. All patient identifiers 
were deleted after LPI codes were added. Each site also created a CDI database based on 
CDC EIP data containing only patients who developed CDI and who appeared in the 
discharge/pharmacy data, regardless of the timing of CDI onset relative to the hospital 
admission. The protocol was approved by the institutional review board at each site and 
CDC.
Analytical Methods
After merging the datasets, the distribution/frequency of all variables was examined, 
including demographics, frequency and risk of CDI following hospitalization, time from 
hospitalization to CDI, length of stay (LOS), antibiotic exposure during stay, ICD-9-CM 
diagnosis and procedure categories, inpatient units, death, disposition on discharge, past 
hospital stays and antimicrobial exposures, and past episodes of CDI.
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Clinical Classification Software (CCS) from the Agency for Healthcare Research and 
Quality (AHRQ) was used to categorize ICD-9-CM diagnosis and procedure codes into 
clinically meaningful categories.[8] For each hospital stay, antimicrobials were grouped into 
twelve classes, described above.
The cohort was created by identifying the hospital stays within a single year for each unique 
patient at each site, January 2011-December 2011 for CT and July 2011-June 2012 for NY. 
Among patients with more than one hospitalization, one stay was selected at random and 
identified as the index hospitalization. Exposures were based on the index hospitalization 
and past hospitalizations within 90 days. All patients with CDI documented either during 
index hospitalization or prior to hospitalization based on EIP data and patients receiving oral 
vancomycin during their index hospitalization were excluded from analysis.
Our outcome was an incident C. difficile episode ≥28 days after discharge from the index 
hospitalization. The timeframe of ≥28 days after discharge for CDI development was used to 
take into account a scenario where the vaccine would be administered at the time of hospital 
discharge, would be a multiple dose regimen, and time would be needed for vaccine 
recipients to build an immune response. In addition, we hypothesized that the vaccine would 
be for prevention of primary CDI, and therefore patients with prior CDI were excluded.[9, 
10]
Exposures were based on information provided by the hospital administrative data while the 
outcome was based on the linked EIP CDI surveillance data.
In order to create a CDI risk index, we considered the scenario of enrollment and 
vaccination at time of hospital discharge to prevent post-discharge incident CDI ≥28 days 
after discharge. We conducted univariate comparisons of those who developed CDI ≥28 
days after discharge to those without CDI using t-tests or Wilcoxon Rank tests for 
continuous variables and Chi Square or Fisher's Exact tests for categorical variables as 
applicable.
In the multivariate analysis, we employed a Cox Proportional Hazards model and conducted 
a backward elimination selection with a significance level to stay criterion of p ≤0.10 to 
identify important predictors of CDI after discharge. Due to the large number of CCS 
categories, univariate analysis was used to categorize each of the following CCS categories: 
discharge diagnosis, procedure and admission diagnosis into four progressive levels 
depending on the increasing association with CDI ≥28 days post-discharge. Patients were 
followed until the development of CDI during the post-discharge period, death, or the end of 
follow-up period. The follow-up period extended to six months following the end of the 
initial year in which index visits were identified, June 30, 2012 for CT and December 31, 
2012 for NY.
After determining the important predictors for CDI development ≥28 days after discharge, 
we developed a CDI risk index. The risk index was based on parameter estimates from the 
Cox Proportional Hazards model containing only important predictors. To generate the risk 
index score, the remaining parameter estimates were divided by the absolute value of the 
smallest parameter estimate. The integer of that quotient was then declared the number of 
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points to assign for that characteristic. Protective characteristics retained a negative score. 
Reference categories were assigned a point value of 0. Once points were assigned for each 
characteristic, all points were summed to calculate a final score for each discharge. 
Distribution of scores was compared for those with CDI ≥28 days following discharge to 
those without. A specific score, the first quartile of those with CDI, was selected to divide 
discharges into high and low risk categories.
In order to validate our CDI risk index, we developed models for each site separately, and 
then validated the model at the other site. For validation, we employed the same outcome, 
and conducted logistic regression in the validation site. For validation, we considered 3 
measures: area under the receiver operating characteristic (ROC) curve for the risk index 
score, odds ratio (OR) for the high risk discharges compared to low risk, and the risk in the 
both the high and low risk discharges.
Further, we conducted three sets of models. The first model (complex scenario) included all 
information in the multivariate models such as ICD-9-CM discharge and procedure codes, 
which may not be readily available in medical records at time of patient's discharge. The 
second model (simple scenario) did not include billing data such as ICD-9-CM discharge 
and procedure codes and information generated from those codes like Gagne co-morbidity 
score and the number of ICD-9-CM procedures. For both the complex and simple scenario, 
models were developed in each site independently and validated at the other site. Finally, a 
third model (combined scenario) was created based on overlapping predictors from the 
complex and simple scenarios. For this model, discharge data from the two sites were 
combined and randomly separated into development and validation cohorts. A Cox model 
including only the selected overlapping predictors and using the data from the development 
cohort was used to develop the risk index for the combined model. That risk index was then 
assessed in the validation cohort.
All analyses were conducted using SAS software (version 9.3; SAS Institute).
Results
A total of 22,069 index hospitalizations were observed in CT from January 1–December 31, 
2011, while 14,527 index hospitalizations were identified in NY from July1, 2011–June 30, 
2012 among surveillance area residents.
At CT, of the 22,069 index hospitalizations, a total of 660 were sequentially excluded using 
the following order: prior CDI (n=105), death during hospitalization (n=402), incident CDI 
during the hospital visit (n=100), and reported oral vancomycin use during the index visit 
(n=53), leaving 21,409 (97%) index hospitalizations for analysis.
At NY, of the 14,527 index hospitalizations, a total of 750 were sequentially excluded using 
the following order: prior CDI (n=279), death during hospitalization (n=390), incident CDI 
during the index hospitalization (n=80), and reported oral vancomycin use during the index 
visit (n=1), leaving 13,777 (95%) index hospitalizations for analysis.
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CDI ≥28 days post-discharge occurred in 164 (0.77%) and 124 (0.90%) of CT and NY 
patients respectively for a total of 288 (0.82%) CDI cases. Based on univariate analysis 
across the two sites, older patients, white race, Medicare primary coverage, prolonged LOS, 
discharge to long term care/skilled nursing facility, higher co-morbidity score [11], prior 
hospitalization within 90 days, additional days in critical care units, ICD-9-CM diagnosis/
procedure/admission diagnosis, prolonged antibiotic therapy and higher number of antibiotic 
classes received during hospitalization were associated with increased risk of CDI ≥28 days 
after discharge (Table 1). Certain antibiotic classes such as cephalosporins, 
fluoroquinolones, intravenous vancomycin, sulfonamides and beta-lactams/beta-lactamase 
inhibitor combinations were associated with increased CDI risk.
A multivariate Cox proportional hazards model was then developed for each site using CDI 
≥28 days post discharge as the outcome. The backward elimination procedure was employed 
starting with all the variables identified in the univariate analysis (Table 1).
For the complex model, after backward selection, the following variables remained 
associated with increased risk of CDI after discharge for both sites: age, ICD-9-CM 
diagnosis, procedure and admission diagnosis CCS risk category, number of ICD-9-CM 
procedure codes, and number of past hospital visits within 90 days. For CT, the number of 
different antibiotic classes administered during index hospitalization also remained, while at 
NY, gender, co morbidity score, and maternity and specialty care wards also remained. In 
addition, each site had specific antibiotic classes associated with increased risk of CDI after 
discharge, however, none overlapped.
A similar multivariate Cox proportional hazards model was developed for each site, but only 
variables expected to be readily available at time of discharge were included (simple 
scenario). After backward selection, ICD-9-CM admission diagnosis CCS risk category, 
older age, , and previous hospitalization remained in the model at both sites. For CT, number 
of antibiotic classes, receipt of 3rd/4th generation cephalosporin, primary payer, past hospital 
antibiotic exposure within 90 days of index hospitalization, and admission to specialty care 
ward also significantly associated with CDI post discharge. For NY, use of clindamycin or a 
fluoroquinolone during index hospitalization, prolonged LOS, gender, and exposure to 
wards other than surgical, medical, critical care, labor and delivery, and emergency 
department also remained in the model.
At each site for both complex and simple models, a risk score was developed. This risk 
score was then validated at the other hospital site as a cross site validation cohort. In the 
derivation cohorts, the risk score performed well. However, when the risk score was applied 
to the cross site validation cohort, performance dropped considerably. For example, in the 
cross site validation cohorts, the area under the ROC curve typically was estimated to be 
around 0.7 even though the estimated area was much higher in the derivation cohorts, >0.8 
(Table 2). The models developed at each individual site did not perform as well when 
implemented at another hospital, likely due to inconsistency in important predictors between 
the two sites.
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Since cross site validation models did not perform well, a third model (combined scenario) 
based on overlapping variables from the simple model and the complex model was 
developed. The combined model included ICD-9-CM admission diagnosis CCS risk 
category, age, past hospitalizations, and 3rd/4th generation cephalosporin, clindamycin, or 
fluoroquinolone use during index hospitalization. For the admission diagnosis risk category, 
only overlapping risk categories (n=24) were included, Table 4.
Cohorts from CT and NY were combined then randomly separated into development and 
validation cohorts. Data from the development cohort was used to create the risk index. As 
previously, that risk index was assessed in the validation cohort. Compared to the cross site 
validation cohorts, performance improved in the validation cohort for the combined model. 
The area under the ROC curve improved to 0.75 and was consistent between both sites, 
suggesting that simple models using only four consistent variables performed better than 
previous models.
To develop a final model, the randomization, model estimation, and creation of the risk 
score index was conducted 500 times. The average area under the ROC curve was 0.75. The 
final risk index score was based on the repeated 500 samples, Table 3. An additional model 
using LOS in place of admission diagnosis categories performed nearly as well, c-
score=0.74, Table 2 and Table 3.
The cut off point for high vs. low risk groups was arbitrarily set at the 25th percentile of the 
derivation cohort for those with CDI, Table 2. However, this point can range and be 
adjusted. As the score increases, the proportion of the cohort who would be included in the 
high risk group decreases while the CDI attack rate in that group increases. We further 
generalized to the situation in which a preventative trial, such as a vaccine trial, is to be 
designed. We estimated the sample size required from the attack rate and further determined 
the estimated proportion at high risk to determine the feasibility of the trial. For our 
example, we assumed a similar hospital with 20,000 index visits, and an efficacy of 50%. 
We then plotted the necessary sample size and the estimated number at high risk for each 
risk score (Figure 1). For risk index scores up to 7, the number expected to be at high risk 
was greater than the estimated sample size.
Discussion
Our study identified specific parameters for a risk index that can be applied at hospital 
discharge to identify a patient population with increased risk of CDI ≥28 days after 
discharge that could be targeted for vaccine trials. The CDI risk index performed well in the 
two academic centers studied, and validation of the risk index observed an CDI attack rate 
≥28 days following hospitalization of 1.5%–2.0% with the risk of CDI among high-risk 
patients being 5 times greater than other patients. The risk index was developed using 
parameters that are likely to be readily available at the time of discharge.
Previous CDI risk-prediction models only took into consideration CDI developing during 
the time of hospitalization or were prediction models developed for recurrent CDI.[12-14] 
Because EIP CDI surveillance is a longitudinal population-based surveillance that includes 
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both inpatient and outpatient laboratories, we are able to capture CDI episodes occurring 
among the population under surveillance including those occurring in the post-discharge 
period.
Most of the factors we found to be associated with post-discharge CDI development such as 
age, LOS, exposure to high risk antibiotics, and past hospital visits are not surprising. 
However, development of scores associated with those risk factors and the determination of 
CDI attack rates based on a patient's overall score provide further insights into the design of 
clinical trials to evaluate interventions for CDI prevention. As demonstrated by our study, 
using very high risk scores in study designs will substantially decrease the number of 
patients eligible to be included and could result in study failure as the necessary sample size 
will unlikely be reached.
There were several limitations in this analysis. First, while administrative data was used in 
conjunction with other data creating a potential for misclassification,[15, 16] we expect any 
bias due to misclassification to be non-differential and not substantial.[17] Second, since our 
combined model used data from both hospitals and certain minority populations may not be 
well represented, data from additional hospitals would help determine the generalizability of 
our risk index. However, our risk index has recently been validated using administrative data 
from a large number of hospitals.[18] In addition, especially for the complex scenario, 
implementing the risk index in a clinical setting would likely be difficult. Even for the 
models using only four variables, implementing the index in a clinical setting may not be 
straight forward due to the admission diagnosis categorization. Using LOS in place of 
admission diagnosis produced a model that performed nearly as well. Such a model may be 
more suitable to explore in other hospitals given potential differences between coding 
practices. Further, choosing an appropriate cut off point to divide cohorts into high and low 
risk discharges was highly subjective, but that allows the risk index to be applied in other 
situations depending on the needs of the trial or study. Finally, while our analysis included 
CDI cases identified in both inpatient and outpatient settings, data on healthcare encounters 
or antibiotic exposures outside of the hospital, including information on antimicrobials 
prescribed at discharge, was not obtained. Outpatient encounters and pharmacy data could 
be important risk factors not accounted for in this analysis, and our final variables included 
in the risk score may be correlated with certain risk factors outside the hospital. However, 
while the inclusion of such data could improve our model and identify additional risk 
factors, the goal of this analysis was to identify a cohort based upon hospital data.
Our study had a number of strengths. First, confirmed CDI cases from EIP surveillance 
linked to hospital administrative data were used. Therefore, our outcome did not rely on 
ICD-9-CM codes which do not always reliably identify incident cases of CDI. Further, cases 
were not limited to those identified only in a hospital setting. There were a large number of 
index hospitalizations, greater than 35,000, included in the study. In addition, our data 
included pharmacy data which is not always readily available from large hospital data sets. 
This novel dataset observed consistent findings with past studies of CDI in a previously 
reported study observing an increased risk of CDI for patient receiving broad spectrum 
antibiotics.[19] Finally, by using two large academic hospitals we were able to validate the 
risk index, and identify predictors consistent at both sites.
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In conclusion, we identified specific parameters for a risk index that can be applied at 
discharge to identify a patient population with increased risk of CDI ≥28 days following an 
acute care hospitalization. The CDI risk score we developed can provide insight for study 
designs to evaluate interventions to prevent CDI; a disease that affects millions of 
individuals and causes thousands of deaths.
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In order to determine the feasibility of a vaccine trial, we estimated the required sample size 
and proportion of patients at high risk available to be included in a vaccine trial for a range 
of risk scores based on the final risk score developed in our model. For our example, we 
assumed a hospital with 20,000 annual patient index visits, and a vaccine efficacy of 50%, 
and we then plotted the necessary sample size and the estimated number at high risk for each 
risk score. For risk index scores up to 7, the number expected to be at high risk was greater 
than the estimated sample size.
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Female 167 57.99% 21102 60.47%
Male 121 42.01% 13796 39.53%
Age Category p<0.0001
18-39 22 7.64% 11693 33.51%
40-49 29 10.07% 4912 14.08%
50-64 92 31.94% 8168 23.41%
65-74 44 15.28% 4209 12.06%
75+ 101 35.07% 5916 16.95%
Race p=0.0002
White 214 74.31% 22825 65.40%
Black 59 20.49% 7318 20.97%
Hispanic 13 4.51% 3309 9.48%
Other 2 0.69% 1446 4.14%
Primary Insurance p<0.0001
Medicare 184 63.89% 12171 34.88%
Medicaid 44 15.28% 6988 20.02%
Private 56 19.44% 14509 41.58%
Other 4 1.39% 1230 3.52%
Number of ICD9 Procedures p=0.0037
0 100 34.72% 11608 33.26%
1 65 22.57% 7767 22.26%
2 46 15.97% 5904 16.92%
3 25 8.68% 4239 12.15%
4 9 3.13% 2155 6.18%
5+ 43 14.93% 3225 9.24%
Length of Stay p<0.0001
1 39 13.54% 7848 22.49%
2 40 13.89% 7670 21.98%
3 33 11.46% 5751 16.48%
4 29 10.07% 3649 10.46%
5 26 9.03% 2279 6.53%
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Cases Non-Cases p-value
6-9 54 18.75% 4357 12.48%
10+ 67 23.26% 3344 9.58%
Admission from Location p=0.1521
Acute Care Hospital 10 3.47% 740 2.12%
LTACH 0 0.00% 0 0.00%
Home/Outpatient 269 93.40% 33408 95.73%
LTC/SNF 8 2.78% 501 1.44%
Other 1 0.35% 249 0.71%
Discharge to Location p<0.0001
Acute Care Hospital 8 2.78% 670 1.92%
LTACH 3 1.04% 131 0.38%
Home/Outpatient 207 71.88% 30016 86.01%
LTC/SNF 65 22.57% 3549 10.17%
Other 5 1.74% 532 1.52%
Gagne Co-Morbidity Score p<0.0001
0 or less 42 14.58% 6786 19.45%
1 40 13.89% 7227 20.71%
2 55 19.10% 3714 10.64%
3 34 11.81% 2166 6.21%
4+ 98 34.03% 4103 11.76%
No score 19 6.60% 10902 31.24%
Past Hospital Visits within 90 days p<0.0001
0 204 70.83% 31063 89.01%
1 60 20.83% 2960 8.48%
2+ 24 8.33% 875 2.51%
Days in critical care p<0.0001
0 235 81.60% 31325 89.76%
1 10 3.47% 1252 3.59%
2 10 3.47% 825 2.36%
3 6 2.08% 450 1.29%
4 5 1.74% 270 0.77%
5+ 22 7.64% 776 2.22%
ICD9 CCS Diagnosis Category p<0.0001
2-Septicemia 16 5.56% 576 1.65%
237-Complication of device/implant/graft 12 4.17% 560 1.60%
108-CHF nonhypertensive 11 3.82% 603 1.73%
159-UTI 10 3.47% 489 1.40%
50-Diabetes mellitus w complications 9 3.13% 476 1.36%
122-Pneumonia 9 3.13% 568 1.63%
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Cases Non-Cases p-value
157-Acute Renal Failure 7 2.43% 398 1.14%
109-Acute CVD 6 2.08% 551 1.58%
197-Skin infections 6 2.08% 589 1.69%
238-Complications of surgical procedures/medical care 6 2.08% 390 1.12%
Other 196 68.06% 29698 85.10%
ICD9 CCS Procedure Category p<0.0001
None 100 34.72% 11634 33.34%
216-Mechanical ventilation 13 4.51% 556 1.59%
61-Other OR procedures on vessels 8 2.78% 332 0.95%
108-Indwelling catheter 8 2.78% 433 1.24%
54-Other vascular catheterization 7 2.43% 282 0.81%
58-Hemodialysis 6 2.08% 225 0.64%
179-CT scan abdomen 6 2.08% 338 0.97%
146-Treatment, fracture, dislocation of hip 6 2.08% 246 0.70%
193-Diagnostic ultrasound of heart 5 1.74% 383 1.10%
205-Arterial blood gases 5 1.74% 278 0.80%
224-Cancer chemotherapy 5 1.74% 112 0.32%
Other 119 41.32% 20079 57.54%
ICD9 CCS Admission Diagnosis Category p<0.0001
259-Unclassified 16 5.56% 819 2.35%
251-Abdominal pain 12 4.17% 1040 2.98%
133-Other lower respiratory disease 12 4.17% 1005 2.88%
245-Syncope 11 3.82% 685 1.96%
122-Pneumonia 10 3.47% 531 1.52%
197-Skin infections 10 3.47% 632 1.81%
102-Nonspecific chest pain 9 3.13% 1211 3.47%
127-COPD 7 2.43% 213 0.61%
157-Acute Renal Failure 7 2.43% 204 0.58%
Other 194 67.36% 28558 81.83%
Days on antibiotics p<0.0001
0 130 45.14% 19078 54.67%
1 8 2.78% 3679 10.54%
2 23 7.99% 3143 9.01%
3 11 3.82% 2047 5.87%
4 18 6.25% 1483 4.25%
5 22 7.64% 1021 2.93%
6 4 1.39% 817 2.34%
7 10 3.47% 660 1.89%
8 7 2.43% 525 1.50%
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Cases Non-Cases p-value
9 5 1.74% 398 1.14%
10 7 2.43% 309 0.89%
11 4 1.39% 253 0.72%
12 5 1.74% 211 0.60%
13 4 1.39% 165 0.47%
14 4 1.39% 148 0.42%
15+ 26 9.03% 961 2.75%
0.00% 0
Antibiotic Class (Ever)
Aminoglycosides 7 2.43% 695 1.99% p=0.5957
1st and 2nd Gen Cephalosporins 33 11.46% 6378 18.28% p=0.0028
3rd and 4th Gen Cephalosporins 59 20.49% 2713 7.77% p<0.0001
Lincosamides 8 2.78% 1151 3.30% p=0.6222
Fluoroquinolones 68 23.61% 3723 10.67% p<0.0001
Macrolides 7 2.43% 686 1.97% p=0.5718
Vancomycin IV 30 10.42% 1586 4.54% p<0.0001
Sulfa 19 6.60% 952 2.73% p<0.0001
Beta-lactam/Beta-lactamase inhibitor combinations 61 21.18% 3231 9.26% p<0.0001
Carbapenems 5 1.74% 441 1.26% p=0.4207
Penicillins 7 2.43% 1733 4.97% p=0.0481
Other 45 15.63% 3381 9.69% p=0.0007
Number of different antibiotic classes p<0.0001
0 130 45.14% 19078 54.67%
1 58 20.14% 9044 25.92%
2 40 13.89% 4076 11.68%
3 35 12.15% 1747 5.01%
4 20 6.94% 656 1.88%
5+ 5 1.74% 297 0.85%
Days on Antibiotics within Past 90 Days of index visit p<0.0001
0 242 84.03% 33305 95.44%
1 2 0.69% 186 0.53%
2 2 0.69% 219 0.63%
3 9 3.13% 163 0.47%
4 4 1.39% 134 0.38%
5 2 0.69% 105 0.30%
6 0 0.00% 104 0.30%
7 6 2.08% 87 0.25%
8 1 0.35% 74 0.21%
9 0 0.00% 66 0.19%
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Cases Non-Cases p-value
10+ 20 6.94% 455 1.30%
Unit Type Ever
Critical Care (CC) 57 19.79% 5046 14.46% p=0.0105
Emergency Department (ED) 106 36.81% 9312 26.68% p=0.0001
Labor and Delivery/Maternity (MAT) 3 1.04% 5651 16.19% p<0.0001
Speciality Care (SCA) 31 10.76% 1056 3.03% p<0.0001
Medical Ward (WARD) 146 50.69% 14820 42.47% p=0.0049
Surgical Ward (SURG) 99 34.38% 10150 29.08% p=0.0491
Psych 1 0.35% 948 2.72% p=0.0134
Other 29 10.07% 2809 8.05% p=0.2099
Inpatient Gerontology Ward (W-GNT) 11 3.82% 781 2.24% p=0.0716
Inpatient Gynecology Ward (W-GYN) 7 2.43% 2206 6.32% p=0.0068
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